SCHEMBL25323518

SCHEMBL25323518

COc1ccc(OC)c2c1sc1nnc(NC(C)=O)n12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PARP2 Q9UGN5 7/20 1.00
▸ TNKS2 Q9H2K2 4/20 0.69
▸ PARP15 Q460N3 3/20 0.69
▸ PARP10 Q53GL7 2/20 0.59
▸ TNKS O95271 1/20 0.59
▸ PARP1 P09874 1/20 0.59
▸ PARP6 Q2NL67 1/20 0.59
▸ PARP14 Q460N5 1/20 0.59
▸ TIPARP Q7Z3E1 1/20 0.59
▸ PARP16 Q8N5Y8 1/20 0.59
▸ PARP12 Q9H0J9 1/20 0.59
▸ PARP11 Q9NR21 1/20 0.59
▸ PARP4 Q9UKK3 1/20 0.59
▸ PARP3 Q9Y6F1 1/20 0.59
▸ ADORA2A P29274 1/20 0.43
▸ ADORA2B P29275 1/20 0.43
▸ ADORA1 P30542 1/20 0.43
▸ ALDH1A1 P00352 7/20 0.40
▸ HSD17B10 Q99714 3/20 0.40
▸ KDM4E B2RXH2 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25322173 0.86 PARP2 (1.00) PARP2TNKS2PARP15PARP10TNKS
SCHEMBL25322731 0.75 PARP2 (1.00) PARP2TNKS2PARP15PARP10TNKS
SCHEMBL11749369 0.67 DYRK1A (0.54) PARP2ADORA1ALDH1A1KDM4EHPGD
SCHEMBL25325363 0.64 PARP2 (1.00) PARP2TNKS2PARP15PARP10TNKS
SCHEMBL25325548 0.64 PARP2 (0.59) PARP2TNKS2PARP15PARP10TNKS
SCHEMBL25322921 0.64 PARP2 (1.00) PARP2TNKS2PARP15PARP10TNKS
SCHEMBL25324132 0.63 PARP2 (0.74) PARP2TNKS2PARP15PARP10TNKS
SCHEMBL3057508 0.61 ADORA2A (0.61) PARP2ADORA2AADORA2BADORA1ALDH1A1
SCHEMBL9753618 0.60 ALDH1A1 (0.56) ADORA2AADORA2BALDH1A1KDM4ENPC1
SCHEMBL30675555 0.60 ADORA3 (0.51) ADORA2AADORA2BALDH1A1KDM4ETSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250177359-A1 COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS OULUN YLIOPISTO (FI) 2025-06-05 — — US disclosed
EP-4469046-A1 COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS Oulun Yliopisto (FI) 2024-12-04 — — EP disclosed
WO-2023144450-A1 COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS OULUN YLIOPISTO (FI) 2023-08-03 — — WO disclosed
WO-2023144450-A1 COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS OULUN YLIOPISTO (FI) 2023-08-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250177359-A1 COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS NAMPT, NADK, NQO1 PARP2 15/4885TNKS2 29/4885PARP15 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback